Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.
Helena TaflinElisabeth OdinGöran CarlssonRoger TellBengt GustavssonYvonne WettergrenPublished in: Cancer chemotherapy and pharmacology (2020)
NCT02244632, first posted on ClinicalTrials.gov on September 19, 2014.